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http://dContents lists available at ScienceDirectEditorialWhere do we stand on human diabetic nephropathy?The prevalence of type 2 diabetes is rising rapidly in Asian
populations due to lifestyle changes and increased life expec-
tancy. With the rapidly increasing number of patients with
diabetes worldwide, diabetic nephropathy (DN) is becoming
one of the most common causes of renal disease. Indeed,
approximately 20–40% of diabetic patients develop DN [1]. The
diagnosis of DN is based primarily on clinical features such as
lengthy duration of diabetes and presence of target organ
damage, especially proteinuria usually preceding decreased
renal function. Although validation of this clinical approach is
well established in type 1 diabetes, it is much more difﬁcult in
patients with type 2 diabetes because of the unknown dura-
tion of the disease [2]. The characteristic pathological features
of DN are diffuse or nodular mesangial sclerosis, glomerular
basement membrane thickening accompanied by chronic
interstitial ﬁbrosis and tubular atrophy usually observed in
advanced glomerulosclerosis, and hyaline changes in both
afferent and efferent arterioles. However, nondiabetic renal
disease (NDRD) occurs in patients with type 2 diabetes, and
can be either isolated or superimposed on underlying diabetic
glomerulosclerosis. Interestingly, NDRD is associated with a
broad spectrum of symptoms [3–5]. The ability to clearly
differentiate between renal lesions associated with DN and
NDRD in diabetic patients is critical for making appropriate
treatment decisions, and thus numerous research efforts are
focused on how to identify DN in patients with diabetes.
Recently, Liang et al [5] performed a meta-analysis of 26
relevant studies comprising 2,322 patients and suggested that
the absence of diabetic retinopathy (DR), shorter duration of
diabetes, lower HbA1C, and lower BP may help to distinguish
NDRD from DN in patients with diabetes [5]. In this issue of
Kidney Research and Clinical Practice, Kim et al [6] retrospec-
tively analyzed renal pathological ﬁndings including the inci-
dence of NDRD in 75 diabetic patients who underwent renal
biopsy for clinically suspected NDRD. They also analyzed the
clinical characteristics and renal prognosis of patients with DN
and NDRD. They found that 10 patients (13.3%) had only DN, 11
patients (14.7%) had DN with superimposed NDRD, and 54
patients (72%) had only NDRD. The most common pathological
ﬁndings of NDRD were membranous nephropathy (23.1%), IgA
nephropathy (21.5%), and acute tubulointerstitial nephritis
(15.4%). Compared with DN and NDRD superimposed on DN,
the clinical characteristics of NDRD consisted of a short
duration of diabetes and less severe DR. Conversely, patients
with combined DN and NDRD exhibited the lowest baseline32/$ - see front matter & 2013. The Korean Society of Nephrology. Publi
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
x.doi.org/10.1016/j.krcp.2013.07.007estimated glomerular ﬁltration rate (eGFR) with the greatest
proportion of renal deterioration during follow-up. Based on
these ﬁndings, Kim et al [6] concluded that renal biopsy should
be recommended for type 2 diabetic patients with atypical
nephropathy, because a considerable number of these patients
may have NDRD. However, there were several limitations in
their study. First, pathological determination of DN and NDRD
was based only on histological ﬁndings by light microscopy
rather than by electron microscopy. Because the early stages of
DN may not be observed with light microscopy, electron
microscopy ﬁndings may provide a clearer differentiation of
renal lesions. Second, the follow-up duration for patients with
NDRD was much shorter compared to that in patients with DN,
and thus determination of renal prognosis was not appropriate
between groups with different follow-up periods.
Recent updates in the ﬁeld of human DN
The most conspicuous recent ﬁndings in the ﬁeld of DN has
been the identiﬁcation of a number of biomarkers pertinent to
the diagnosis of DN and a new pathology classiﬁcation system
launched in 2010 by the Research Committee of the Renal
Pathology Society [7]. Highly heterogeneous renal lesions and a
more unclear structure–function relationship in type 2 diabetes
mellitus compared with type 1 diabetes mellitus has been
reported, and thus combining the analysis of pathological grad-
ing and new biomarkers for DN will further increase our under-
standing of this complex disease manifestation. The pathogenesis
of DN has a number of complex characteristics, with diverse
renal pathological lesions observed in patients with type 2 dia-
betes. Although the number of patients with type 2 diabetes is
rapidly increasing worldwide, DN is paradoxically the renal
disease for which the fewest renal biopsies are performed. In
many centers, DN is diagnosed on the basis of clinical parameters
without renal biopsy. Speciﬁcally, renal biopsy is performed only
for a small population of diabetic patients, typically cases with
unusual clinical presentation such as sudden onset of nephrotic
syndrome or sudden decrease in renal function, and then to
exclude causes other than DN. As a result, there is insufﬁcient
clinical data regarding histopathological issues in DN.
New histopathological classiﬁcation system for DN
The new classiﬁcation system launched in 2010 distin-
guishes between four classes of DN, where essentially onlyshed by Elsevier. This is an open access article under the CC BY-NC-ND
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terized by the absence of histological lesions (Class I), mesan-
gial changes (Class II), nodular lesions (Class III), or a
predominance of global glomerulosclerosis (Class IV) [7].
However, this new classiﬁcation system has not yet been fully
validated, as it is unclear whether it can differentiate between
DN in type 1 and type 2 diabetic patients. Speciﬁcally, the
new classiﬁcation system dictates that the only differences
between DN in type 1 and type 2 diabetic patients are that the
latter group has a more heterogeneous clinical course and
more diverse renal lesions, as well as the difference in the
relationship between DN and DR. It has generally been held
that virtually all patients with type 1 diabetes and overt
nephropathy have DR, whereas o 50% of patients with type
2 diabetes and DN have DR [8]. However, Pedro et al [9] looked
at the prevalence and relationship between DN and DR in a
population-based study in Spain, including 8,187 patients with
type 2 diabetes and 488 patients with type 1 diabetes, and
found that although the relationship between microalbumi-
nuria and DR differs between type 1 and type 2 diabetics, the
relationship between overt nephropathy and DR is similar in
both types. Additionally, they found that overt nephropathy is
a risk factor for DR in both types of diabetes. There are several
other unresolved issues in the new classiﬁcation system for
DN, including whether the heterogeneity of histopathological
lesions in DN represents only differences in time-points of the
disease, whether different lesions have different pathophysio-
logical mechanisms, and whether the new classiﬁcation sys-
tem can predict a more heterogeneous course of type
2 diabetes. Nevertheless, the revised paradigm represents a
very important ﬁrst step toward the development of a clini-
cally useful classiﬁcation system for DN.Recent biomarker studies in human type 2 diabetic
patients
A number of recent studies have reported new biomarkers
for DN, especially in type 2 diabetics. Yan et al [10] reported an
association between plasma concentrations of osteopontin and
the presence and severity of DN in type 2 diabetics. In another
study, plasma levels of methylglyoxal, a metabolic side-pro-
duct, were found to be signiﬁcantly higher in patients with
type 2 DN than in those without DN, and correlated with
urinary albumin excretion [11]. In addition, ﬁbroblast growth
factor 23 was found to be predictor of renal outcome in type
2 diabetics with macroalbuminuria [12]. Furthermore, baseline
serum ﬁbroblast growth factor 23 levels showed a signiﬁcant
association with serum creatinine and proteinuria. However,
the most signiﬁcant problem of such biomarker studies is the
lack of validation in a study population by renal biopsy.Accurate assessment of DN
A large number of clinical trials have been performed to
identify DN in patients with diabetes without renal biopsy.
Unfortunately, a major limitation in most of these biomarker
studies is the absence of renal biopsy to determine the presence
and severity of DN. Instead, virtually all such studies use albumi-
nuria for the diagnosis of DN. However, chronic renal insufﬁciency
and albuminuria may be derived from NDRD rather than classic
DN, especially in type 2 diabetics. In a recent retrospective study of69 patients with type 2 diabetes, 52% of patients with renal lesions
conﬁrmed by renal biopsy had NDRD rather than DN [13].
Nevertheless, care must be taken when interpreting the results
of clinical studies using renal biopsies, because they are often
performed if comorbidity is suspected, leading to selection bias.
This important issue can also be applied to recent biomarker
studies, where some patients were erroneously given a diagnosis
of DN. Indeed, only one biomarker study used renal biopsy as well
as urine proteome analysis, the results of which were used to
propose a reliable classiﬁcation model to differentiate between DN
and NDRD, where ubiquitin and β2-microglobulin expressionwere
among the best predictors of DN [14]. The major advantage and
clinical relevance of this study was the considerable proportion of
study patients who were at the beginning stages of DN without
albuminuria. Araki et al [15] serially observed changes in urinary
levels of type IV collagen in 254 patients with nonovert DN in type
2 diabetics. They observed that baseline urinary type IV collagen
levels are higher in patients with microalbuminuria, and during a
follow-up study with a median duration of 8 years, they found
that levels of urinary type IV collagen inversely correlate with the
annual decline in estimated GFR, whereas overt proteinuria does
not manifest in the majority of patients. Inclusion of histopatho-
logical information from renal biopsy in these types of biomarker
studies would certainly make a great contribution toward a better
understanding of the mechanisms leading to DN.Conclusion
DN exhibits signiﬁcant pathological diversity, especially in
patients with type 2 diabetes; however, there is little informa-
tion regarding different mechanisms for various cases of
NDRD. At present, the diagnosis of DN is based on typical
clinical symptoms without renal biopsy. A new classiﬁcation
system launched in 2010 has the potential to be easy to use
internationally in clinical practice, and aims to distinguish
between different types of DN by identifying four hierarchical
glomerular lesion types, with a separate evaluation for degrees
of interstitial and vascular involvement. However, several
unresolved issues remain in the new classiﬁcation system,
including whether the more heterogeneous course in type
2 diabetic patients can be predicted. Recent clinical efforts
have focused on noninvasive identiﬁcation of new biomarkers
from plasma or urine for early detection of DN, differentiation
from NDRD, and the clinical utility of these biomarkers for
predicting renal outcome in patients with DN. Unfortunately,
the majority of these recent biomarker studies have included
neither renal biopsy nor histopathological diagnosis. Thus,
combining histopathological grading and biomarkers for DN
promises to provide a more reliable understanding of this
complex disease manifestation.Conﬂicts of interest
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